{"id":"W2093783077","doi":"10.1158/1078-0432.ccr-06-2309","title":"Phase II Trial of Bevacizumab and Irinotecan in Recurrent Malignant Glioma","year":2007,"lang":"en","type":"article","venue":"Clinical Cancer Research","topic":"Glioma Diagnosis and Treatment","field":"Medicine","cited_by":1075,"is_retracted":false,"has_abstract":true,"ca_institutions":"Immunovaccine (Canada)","funders":"National Institute of Neurological Disorders and Stroke; National Cancer Institute","keywords":"Medicine; Bevacizumab; Irinotecan; Glioma; Surgery; Internal medicine; Chemotherapy; Gastroenterology; Cancer; Colorectal cancer","routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":false},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"codex-gemma-dda1882f352a","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0044257,0.0001082297,0.0004911741,0.0003507585,0.0000690227,0.000009201764,0.00009951938,0.00014189,0.0001631339],"category_scores_gemma":[0.0009357502,0.00008036046,0.0001194766,0.0005703453,0.0003560467,0.00002910802,0.0001615267,0.0004963905,0.000007314349],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.0001699167,"about_ca_system_score_gemma":0.0003055321,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.0006654196,"about_ca_topic_score_gemma":0.000716592,"domain_scores_codex":[0.9974654,0.0001888073,0.0008193247,0.0004058882,0.0006524184,0.0004681368],"domain_scores_gemma":[0.9980808,0.0009261773,0.00008328607,0.0003395473,0.0002271341,0.0003430408],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"design_other","study_design_gemma":"randomized_trial","study_design_scores_codex":[0.15647,0.02817805,0.02471254,0.000137303,0.0001128797,0.001189417,0.000234523,2.680051e-7,0.002714444,0.000403114,0.00159165,0.7842557],"study_design_scores_gemma":[0.6986326,0.1171311,0.1119668,0.001227927,0.0001420205,0.0000426451,0.0003149447,0.00009493876,0.04771168,0.0006574137,0.02178612,0.0002917542],"study_design_candidate":"randomized_trial","study_design_consensus":null,"genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.993359,0.002578462,0.000001985925,0.002116848,0.000264248,0.001086727,0.00001871641,0.000009085159,0.0005649733],"genre_scores_gemma":[0.9976918,0.001663522,0.00007147694,0.00003957359,0.0003395111,0.0001145274,0.00000666495,0.00001389404,0.00005908756],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.783964,"threshold_uncertainty_score":0.3277005,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.2874148997796409,"score_gpt":0.5805459813262088,"score_spread":0.2931310815465679,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}